Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone

BackgroundSodium-glucose co-transporter-2 inhibitors (SGLT2i) have cardiovascular (CV) benefits, particularly in reducing the risk of heart failure (HF). Pioglitazone (Pio) has shown potential in decreasing the risks of recurrent stroke, non-fatal myocardial infarction (MI), and all-cause mortality...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yan-Rong Li, Chih-Ching Wang, Chi-Hung Liu, Chieh-Li Yen, Victor Chien-Chia Wu, Evelyn Jou-Chen Huang, Ching-Yu Lee, Ching-Chung Hsiao
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-08-01
Rangatū:	Frontiers in Endocrinology
Ngā marau:	type 2 diabetes mellitus sodium-glucose co-transporter-2 inhibitors (SGLT2i) pioglitazone cardiovascular outcomes heart failure
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1420485/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!